About: Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.99 (+0.76%)
ACRS NASDAQ Aclaris Therapeutics Inc
Aclaris Therapeutics Inc share price
Atividade de preço de ACRS
Último preço
$ 3,990
Variação (24h)
0,03 USD (0,76%)
Volume
1.45M
Volume (média 4 sem.)
-
Abertura
$ 4,05
Variação do dia
$ 3,96 - $ 4,08
Fechamento anterior
$ 3,96
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
ACRS price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals